Sarah Cannon Research Institute
William Donnellan has extensive experience in the field of oncology research and treatment. William worked as a Physician at Tennessee Oncology from 2014 until the present. In 2018, they joined the Sarah Cannon Research Institute as the Director of Leukemia/MDS research.
William Donnellan attended Auburn University from 2000 to 2004, where they studied biomedical science. Their degree program focused on the field of biomedical sciences in general.
This person is not in the org chart
This person is not in any teams
Sarah Cannon Research Institute
Sarah Cannon Research Institute (SCRI) is one of the world’s leading oncology research organizations conducting community-based clinical trials. In 2022, SCRI formed a joint venture with former US Oncology Research to enhance clinical trial access and availability across the country. Focused on advancing therapies for patients over the last three decades, SCRI is a leader in drug development. It has conducted nearly 700 first-in-human clinical trials since its inception and contributed to pivotal research that has led to the majority of new cancer therapies approved by the FDA today. The combined research network brings together physicians who are actively accruing patients to clinical trials at more than 250 locations in 26 states across the US.